Skip to content
Search

Latest Stories

One in five people with risk of heart disease do not know how to check pulse, study says

One in five people in the UK having a personal or familial risk of heart disease do not know how to check their pulse, the simplest way to detect irregular heart rhythms and atrial fibrillation (AF).

The study, conducted by Bristol Myers Squibb in the run up to the National Heart Month, revealed that an early detection and management could improve outcomes for patients.


AF, the most common irregular heart rhythm disorder or arrhythmia is prevalent in around 3 per cent of the UK’s population that can increase the risk of stroke by five times.

It noted that around 300,000 people in the UK are living with undiagnosed AF as the patient experiences minimal or no symptoms at all.

Conducted in November last year, more than two thousand volunteers in the UK aged 16 to 75 participated in the study, which examined the general public’s awareness and understanding of AF and arrhythmia.

it revealed that only 53 per cent of respondents were aware that irregular heart rhythm can cause stroke, while only 13 per cent attend heart health screenings to detect any heart abnormalities.

It also showed 30 per cent of people with a personal or with a family history of heart condition do not recognise symptoms of arrhythmia, and 35 per cent are not aware of ways to reduce the risk.

Trudie Lobban, MBE, founder & trustee of Arrhythmia Alliance, said: “Atrial fibrillation is common especially in the older population who are often living with other heart conditions such as heart failure and high blood pressure.”

“Most commonly, AF is diagnosed during a doctors appointment, however, in March 2020 at the beginning of the Covid-19 pandemic, a 30 per cent drop in attendance to the GP surgery was observed in England. If we can counter the number of potentially missed diagnoses during the pandemic by equipping the general public with the correct knowledge to monitor their heart health and importantly their heart rhythm, we can help prevent serious cardiovascular complications arise, such as AF-related stroke.”

The study also showed that men are more likely to have a personal history of a heart condition as compared with women, and the common symptoms of AF include heart palpitations,  tiredness, shortness of breath and chest pain.

Belinda Sandler, associate director, medical lead, BMS Cardiovascular UK & Ireland said: “We urge people with a personal or family history of a heart condition to regularly check their pulse or, if unsure how, to speak to their GP. If more people actively check their pulse, this can aid early diagnosis and appropriate management of the condition to prevent stroke.”

The research stated a simple pulse check can be used to detect heart rythms, enabling the potential diagnosis of irregular heart rhythm, including AF.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less